Novo Nordisk's amycretin cut A1C and body weight in a phase 2 study, with no plateau seen, as the company targets a 2026 ...

Experts say we’re in a golden age for treating chronic kidney disease, with new drugs like Ozempic yielding major results. Will dialysis and organ transplants become a thing of the past?

The FDA has now started a review of the highly anticipated drug, and AZ is using a priority review voucher to shorten the ...

Novo Nordisk said on Tuesday its experimental obesity drug, amycretin, showed statistically significant weight loss of up to ...

Lexicon Pharmaceuticals, Inc. currently offers three late-stage assets Zynquista, Inpefa & Pilavapadin. Learn more about LXRX ...

Get the latest on Vera Therapeutics, Inc., FDA progress for atacicept, and IgA nephropathy drug competition. Click to what to ...

Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical, Co. Ltd. (Otsuka) today announce the U.S. Food and Drug Administration (FDA) has granted accelerated approval of ...

In recent years, a group of medications called SGLT2 inhibitors has gained a lot of attention. These drugs were first developed to help lower blood sugar levels. They work in the kidneys by blocking a ...

South Africa has slashed HIV deaths by over 20% in two years thanks to world-leading ART access — but diabetes and heart ...

Patients with type 2 diabetes who received sodium-glucose cotransporter-2 inhibitors had a lower risk for rheumatic disease ...

HOUSTON -- SGLT2 inhibitors may hold a benefit for a wider pool of patients with chronic kidney disease (CKD) than previously thought, a pair of meta-analyses indicated. SGLT2 inhibitors helped to ...

A new study shows that older adults with type 2 diabetes who start treatment with sodium–glucose cotransporter-2 (SGLT-2) ...